References
Hildebrandt B, le Coutre P, Nicolaou A et al (2007) Cetuximab: appraisal of a novel drug against colorectal cancer. Recent Results Cancer Res 176:135–143
Vincenzi B, Schiavon G, Silletta M et al (2008) The biological properties of cetuximab. Crit Rev Oncol Hematol 68:93–106
Cunningham D, Humblet Y, Siena S et al (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337–3454
Bonner JA, Harari PM, Giralt J et al (2010) Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11:21–28
Vermorken JB, Mesia R, Rivera F et al (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359:1116–1127
Bibeau F, Lopez-Crapez E, Di Fiore F et al (2009) Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol 27:1122–1129
López-Albaitero A, Lee CS, Morgan S et al (2009) Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells. Cancer Immunol Immunother 58:1853–1862
Kono K, Takahashi A, Ichihara F et al (2002) Impaired antibody-dependent cellular cytotoxicity mediated by herceptin in patients with gastric cancer. Cancer Res 62:5813–5817
de Souza AP, Bonorino C (2009) Tumor immunosuppressive environment: effects on tumor-specific and nontumor antigen immune responses. Expert Rev Anticancer Ther 9:1317–1332
Author information
Authors and Affiliations
Corresponding author
Additional information
Please note that we are simultaneously publishing a letter by Ottaiano et al., which is a response to the paper by López-Albaitero et al., published in 2009 (Cancer Immunol Immunother 58:1853–1862), and a response by Ferris and Ferrone to the Ottaiano letter.
Rights and permissions
About this article
Cite this article
Ottaiano, A., Scala, S. & Iaffaioli, V.R. Cetuximab-dependent ADCC in cancer: dream or reality?. Cancer Immunol Immunother 59, 1607–1608 (2010). https://doi.org/10.1007/s00262-010-0884-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00262-010-0884-3